Reference of 1453-58-3, As an important bridge between the micro and macro material world, chemistry is one of the main methods and means for humans to understand and transform the material world. 1453-58-3, Name is 3-Methylpyrazole, SMILES is CC1=NNC=C1, belongs to pyrazoles-derivatives compound. In a article, author is Azpeitia, Susan, introduce new discover of the category.
Experimental and DFT studies on Hexacoordinated acyl(alkyl)and Pentacooordinated Hydroxyalkyl(phosphinite)erhodium(III). Catalytic Hydrolysis of Ammonia Borane
[Rh(nbd)Cl](2) (nbd=norbornadiene) reacts with quinoline-8-carbaldehyde (C9H6NCHO) and pyrazole (Hpz) affording, depending on Rh/Hpz ratio, acyl-alkyl [Rh(mu-Cl)(C9H6NCO)(Hpz)(sigma-C7H9)](2) (1) or [RhCl(C9H6NCO)(Hpz)(2)(sigma-norbornenyl)] (2), stereoselectively as confirmed by DFT calculations. Hydrogen bond between NH-pyrazole and O-acyl occurs. 1 and 2 react with diphenylphosphine oxide (SPO) giving 16e [RhCl(C9H6NC(nbyl))(Ph2PO)(Hpz)] (3) through SPO kappa(1)-P-coordination, C-C bond coupling between acyl and norbornenyl and outer-sphere O(P)-to-O(C) hydrogen transfer. 3 shows distorted trigonal bipyramidal structure with weak intramolecular (C)-OH…O(=P) and NH…Cl hydrogen bonds. DFT calculations indicate this 16e structure being favoured by sigma- and pi-type orbital multi-overlapping between pyrazole and both the OH…O and chlorine and by intermolecular forces in the crystal. Solutions of 3 contain an equilibrium between trigonal bipyramid and a square-planar pyramid with OH interacting with phosphoryl and NH, confirmed by DFT C-13 NMR calculations. 1 is very efficient homogeneous catalyst for H3N-BH3 hydrolysis to release hydrogen under air.
Reference of 1453-58-3, One of the oldest and most widely used commercial enzyme inhibitors is aspirin, which selectively inhibits one of the enzymes involved in the synthesis of molecules that trigger inflammation. you can also check out more blogs about 1453-58-3.
Reference:
Pyrazole – Wikipedia,
,Pyrazoles – an overview | ScienceDirect Topics